首页工具

ATM-3507

产品编号 T10395L CAS 1861449-70-8

ATM-3507 is an inhibitor of tropomyosin. In human melanoma cell lines, the IC50s are from 3.83-6.84 μM.

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

ATM-3507, CAS 1861449-70-8

规格	价格/CNY	货期
1 mg	￥ 1,290	现货
2 mg	￥ 1,830	现货
5 mg	￥ 2,880	现货
10 mg	￥ 4,970	现货
25 mg	特惠询价	现货

大包装超大折扣，点击咨询

其他形式的 ATM-3507:

ATM-3507 trihydrochloride
询价
ATM-3507 trihydrochloride (1861449-70-8 free base)
询价

选择批次

纯度: 96.36%

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述	ATM-3507 is an inhibitor of tropomyosin. In human melanoma cell lines, the IC50s are from 3.83-6.84 μM.
靶点活性	Tropomyosin (human melanoma cell lines):3.83-6.84 μM
体外活性	The combinations of both tropomyosin inhibitors plus Vincristine are completely cytotoxic in CHLA-20 cells. The cell lines differ in their relative expression of Tpm3.1 as well as in the expression of other isoforms. All 4 cell lines show some degree of synergy as determined by the Chou–Talalay method. The effect is not limited to the vinca alkaloids as a similar combination efficacy using paclitaxel plus TR100 or ATM-3507[1]. After determing the IC50 concentrations for TR100 and ATM-3507 (CHLA-20: 4.99±0.45 μM, CHP-134: 3.83±0.67 μM, CHLA-90: 6.84±2.37 μM, SK-N-BE(2): 5.00±0.42 μM) in each of the neuroblastoma cell lines, combinations of tropomyosin inhibitors plus Vincristine are tested at levels of each drug alone that kill less than 50% of the neuroblastoma cells.
体内活性	The maximal tolerance dose (MTD) for TR100 and ATM-3507 is 60 and 150 mg/kg, respectively. It is found that twice weekly intravenous administration of ATM-3507 also show combination efficacy and it is found that a significant inhibition of tumor growth and prolongation of animal survival using either combination compared with each monotherapy. The median survival of mice increased from 18 days for mice treated with ATM-3507 to more than 49 days for mice treated with the combination. The impact of each treatment or the combination on body weight is minimal. Drug levels are measured following the intravenous administration of ATM-3507 at 30 mg/kg in Balb/c mice (n=3 per time point). The Cmax of ATM-3507 is 5,758 ng/mL and the the t1/2 is 5.01 h. The observed plasma clearance and volume of distribution at steady state of ATM-3507 is 33.8 mL/min/kg and 7.23 L/kg, respectively[1]. The mean half-life of ATM-3507 is 5.01 hrs for the terminal elimination phase. The mean AUC0-t in the plasma is 14,548 ng/h/mL.

分子量	611.79
分子式	C37H46FN5O2
CAS No.	1861449-70-8

存储

store at low temperature,keep away from direct sunlight　|　Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 250 mg/mL (408.64 mM), Sonication is recommended.

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6345 mL	8.1727 mL	16.3455 mL	40.8637 mL
	5 mM	0.3269 mL	1.6345 mL	3.2691 mL	8.1727 mL
	10 mM	0.1635 mL	0.8173 mL	1.6345 mL	4.0864 mL
	20 mM	0.0817 mL	0.4086 mL	0.8173 mL	2.0432 mL
	50 mM	0.0327 mL	0.1635 mL	0.3269 mL	0.8173 mL
	100 mM	0.0163 mL	0.0817 mL	0.1635 mL	0.4086 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Currier MA, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.Mol Cancer Ther. 2017 Aug;16(8):1555-1565.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +